Ally Bridge Group

Private Equity Our initial platform established in 2013. Frank Yu founded Ally Bridge Group in 2013 and is Chief Executive Officer and Chief Investment Officer. In this capacity, Frank is responsible for setting firmwide strategic initiatives and leading investment objectives across high-impact life science transactions in private and public markets globally. Kevin Reilly joined Ally Bridge Group in 2021 and is a Managing Director, Head of Medtech, for the private equity strategy focused on transactions across healthcare subsectors. Andrew Lam joined Ally Bridge Group in 2021 and is a Managing Director, Head of Biotech, for the private equity strategy focused on investments in biotech. Reese Yeh is a Managing Director for Ally Bridge Group’s private equity strategy focusing on deal execution of transactions and investments in biopharmaceuticals. Sebastian Paquette joined Ally Bridge Group in 2021 and is a Principal for the private equity strategy focused on investments in digital health and medical devices. Prior to that, Sebastian founded two healthcare companies focused on surgeon practice restructuring and medical device supply chain efficiency.